Sam J Lubner
Affiliation: University of Wisconsin
- Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium studySam J Lubner
University of Wisconsin, Madison, WI 53792, USA
J Clin Oncol 28:3491-7. 2010..Secondary end points included overall survival (OS), time to progression (TTP), VEGF levels, and molecular studies of EGFR and k-ras...
- A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancerSam J Lubner
University of Wisconsin Carbone Cancer Center, Madison, USA
Clin Colorectal Cancer 9:157-61. 2010..This phase II study explores the efficacy and safety of a 2-day course of oxaliplatin/capecitabine (2DOC), with oxaliplatin given on day 1 and capecitabine given orally every 8 hours in high doses over 6 doses, mimicking FOLFOX6...
- A preclinical and clinical study of lithium in low-grade neuroendocrine tumorsSam J Lubner
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA
Oncologist 16:452-7. 2011..Use of lithium chloride in murine models suppressed carcinoid cell growth, reduced GSK-3β levels, and reduced expression of chromogranin A. This study assessed the efficacy of lithium chloride in patients with NETs...
- A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinomaTabraiz A Mohammed
D O, M S, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, Wisconsin 53792, USA
Oncologist 16:835-43. 2011..Thus, this study aimed to evaluate the role of VPA in treating NETs and to determine whether VPA induced the Notch signaling pathway signaling in vivo...